

# Integrated multidisciplinary approach/Agrica MSA IFR Public Health 99

<https://neurodegenerationresearch.eu/survey/integrated-multidisciplinary-approachagricamsa-ifr-public-health-99/>

## **Title of cohort**

Integrated multidisciplinary approach/Agrica MSA IFR Public Health 99

## **Acronym for cohort**

AMI

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Jean-François

## **Name of Principal Investigator - Last name**

DARTIGUES

## **Address of institution -Institution**

ISPED / INSERM U1219 / Université de Bordeaux

## **Address of institution - Street address**

146 rue Léo Saignat

## **Address of institution - City**

Bordeaux

## **Address of institution - Postcode**

33076

## **Country**

France

## **Website**

## **Contact email**

[jean-francois.dartigues@isped.u-bordeaux2.fr](mailto:jean-francois.dartigues@isped.u-bordeaux2.fr)

## **Funding source**

MSA (Gironde et caisse centrale), AGRICA

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Neurodegenerative disease in general

**Q1b. When are studies on the above condition(s) expected to become possible?**

Already possible

**Q2a. In a single sentence what is the stated aim of the cohort?**

Study of the disease, especially in association with age. Study health care use and social measures for Alzheimers disease and similar syndromes. Compare with the urban areas (3C and PAQUID)

**Q2b. What distinguishes this cohort from other population cohorts?**

Population-based cohort. Rural population retired from agriculture

**Q3a. i) Number of publications that involve use of your cohort to date**

4

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

[http://www.ncbi.nlm.nih.gov/pubmed/?term=AMI+AND+Dartigues\[Author\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=AMI+AND+Dartigues[Author])

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

65

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

until death

**Q4b. Study criteria: what are the inclusion criteria?**

65 or more years old subjects. Retired from an agricultural activity. Resident in one of the selected towns of the countryside of Gironde. Affiliated to MSA and having, for the employees, the AGRICA complementary (70% of the sample). General practitioner in Gironde

**Q4c. Study criteria: what are the exclusion criteria?**

Not being affiliated to MSA

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

1,000-5,000 participants

**Q6a. Please describe what measures are used to characterise participants**

Sociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time. Fasting blood samples were collected at baseline. Brain MRI were performed at baseline and follow-up on a subsample.

**Q6b. Are there additional measures for participants with a clinical disorder?**

Examination by a neurologist or a geriatrician

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

Yes

**If yes please specify**

Primary endpoint: dementia; secondary endpoints: several co-morbidities, among them Parkinson, cancer, diabetes

**Q7. What is the study design (select all that apply)?**

Longitudinal| Prospective cohort

**Q8. Are your cases matched by**

**Q9a. Does your study include a specialised subset of control participants?**

Yes

**Q9b. If your study includes a specialised subset of control participants please describe**

Participants free of the disease can be used as controls

**Q10a. i) Please enter the data collection start date**

01/09/2007

**Q10a. ii) Please enter the data collection end date**

Last follow-up: 2016; however a next follow-up is planned

**Q10a. iii) Is data collection for this study**

Data collection ongoing| Data analysis ongoing| Closed to new patients

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

Yes - intend to apply for funding

**Q11. Is data collected**

Only through the study

**Other please specify here**

Mainly through the study + health insurance data + cancer registry

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

Yes (participants given permission to be re-contacted via PIs)

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (2)**

No

**% available**

**Q13a. Please give information on the format and availability of data stored in a database (3)**

No

**% available**

**Q13a. Please give information on the format and availability of data stored in a database (4)**

No

**% available**

**Other (please specify)**

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (2)**

No

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (3)**

Data held on computer based records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (4)**

No

**% available**

**Please specify language used**

French

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource| Access committee mechanism

**Q15. What data sharing policy is specified as a condition of use?**

No policy exists

**Q16a. Are tissues/samples/DNA available to other groups?**

Yes

**Q16b i) If yes, please describe below:**

Living donors: blood| Living donors: blood derivatives| Living donors: DNA

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

Yes

**Q17. Is information on biological characteristics available to other groups?**

No

**Number of Patients**  
**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

France

**Diseases:**

Neurodegenerative disease in general

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A